drugset
drugset / Trial / NCT06905327

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

NCT06905327 ↗

Phase 1 Completed 56 enrolled Novartis Pharmaceuticals
RandomizedSequentialDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.

Timeline

Start
2023-03-08
Primary completion
2024-09-25
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject QCZ484 Unknown 50 mg Subcutaneous
Subject QCZ484 Unknown 150 mg Subcutaneous
Subject QCZ484 Unknown 300 mg Subcutaneous
Subject QCZ484 Unknown 600 mg Subcutaneous

Indications

hypertensive disorder